News

Kinvard Bio has selected Zer0 to 5ive to support its website refinement efforts, presentation template design, and the creation of its investor slick. The early-stage company is developing a new class of ribosome-targeting antibiotics,helping to address the diminishing effectiveness of existing oral antibiotics due to antimicrobial resistance (AMR).